

## **Report from SSG Morphology/Tumour biology group. Malmö Dec. 2-3, 2019**

The group will continue to review difficult and rare diagnoses.

Future demand of prognostic markers for oncologic treatment (PDL-1, NTRAC etc.).

When needed, help each other with positive controls when starting new techniques. Hopefully between countries.

Problem with legal issues when sending tissue samples, gen data and scanned histology between countries. We will try to find a way to hide patient identity and still be able to discuss cases and have digital consultations/meetings in the future.

Discussion about the new WHO sarcoma book and the need of molecular techniques for diagnosing.

Pehr Rissler